Histone deacetylase inhibition as an anticancer telomerase-targeting strategy

    loading  Checking for direct PDF access through Ovid

Abstract

Aberrant epigenetic regulation of gene expression contributes to tumor initiation and progression. Studies from a plethora of hematologic and solid tumors support the use of histone deacetylase inhibitors (HDACi) as potent anticancer agents. The mechanism(s) of HDACi-induced cancer growth inhibition and cell death are complex and incompletely elucidated. Here, we discuss erroneous epigenetic regulation ofhTERTtranscription in cancer cells and propose that alleviation of an improper acetylation–deacetylation balance at thehTERTpromoter, is one mode by which HDACi induces anticancer effects. We conclude with some pertinent questions and future perspectives arising from the recent impetus in HDACi preclinical and early clinical studies, with particular attention to the cancer stem cell therapeutic paradigm and its relevance to tumor resistance.

Related Topics

    loading  Loading Related Articles